Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
Rhea-AI Summary
Karyopharm (Nasdaq:KPTI) will host an investor conference call on June 2, 2026 at 2:00 p.m. ET to discuss the Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis, following an oral presentation at the 2026 ASCO Annual Meeting.
The event features Karyopharm's senior management and Dr. John Mascarenhas, SENTRY principal investigator. Investors can join via phone or a live audio webcast with slides under “Events & Presentations” in the investor section of Karyopharm’s website, with an archived replay available about two hours after the call.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – KPTI
On the day this news was published, KPTI gained 7.91%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.3% during that session. Argus tracked a trough of -11.9% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $16M to the company's valuation, bringing the market cap to $223.57M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Two biotech peers (e.g., MAIA, INKT) appeared in the momentum scanner, both moving down with a median move of about -3.8%, indicating broader sector pressure rather than KPTI-specific trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 28 | Investor conference | Positive | +1.4% | Jefferies Global Healthcare Conference fireside chat announcement and webcast access. |
| May 14 | Earnings and trials | Positive | +0.6% | Q1 2026 results, reaffirmed guidance, and Phase 3 endometrial trial enrollment completion. |
| May 12 | Investor conferences | Positive | +1.2% | Participation in two May 2026 healthcare investor conferences with live webcasts. |
| May 07 | Earnings date set | Neutral | -1.9% | Scheduling of Q1 2026 earnings release and investor call details. |
| Apr 21 | ASCO selection | Positive | +2.6% | Phase 3 SENTRY myelofibrosis trial chosen for late-breaking ASCO 2026 oral presentation. |
Recent news, especially ASCO-linked SENTRY updates and corporate events, generally saw positive price reactions, with only one divergence on a routine earnings date announcement.
This announcement fits a steady stream of investor-facing catalysts for Karyopharm in Q2 2026. In April 2026, ASCO selected Phase 3 SENTRY myelofibrosis data for a late-breaking oral presentation, which was followed by a 2.57% gain. May brought multiple conference participations and Q1 2026 results with reaffirmed $130–$150 million revenue guidance and SENTRY results disclosure. Today’s investor call around SENTRY deepens that ASCO-focused narrative and ongoing engagement with the oncology community.
Regulatory & Risk Context
An effective Form S-3 filed on 2026-05-04 registers the resale of up to 8,843,036 existing and warrant-related common shares from a March 2026 private placement. The company receives no proceeds from these resales, though the filing facilitates liquidity for holders and reflects a prior financing that generated about $30 million in gross proceeds.
Market Pulse Summary
The stock moved +7.9% in the session following this news. A strong positive reaction aligns with growing focus on the Phase 3 SENTRY myelofibrosis data and its late-breaking ASCO profile. Prior ASCO-related news produced a 2.57% gain, and recent earnings and conference updates also drew supportive moves. However, investors must weigh that an effective S-3 registers resale of 8,843,036 shares from a recent financing, which could influence supply dynamics if enthusiasm fades.
Key Terms
phase 3 medical
myelofibrosis medical
AI-generated analysis. Not financial advice.
– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial –
– Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET –
To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-host-investor-conference-call-featuring-expert-perspectives-on-the-phase-3-sentry-trial-in-myelofibrosis-following-2026-asco-presentation-302786581.html
SOURCE Karyopharm Therapeutics Inc.